Pharmexa Announces that GlaxoSmithKline has Exclusive Option on HER-2 Protein Breast Cancer Project

HORSHOLM, DENMARK


HORSHOLM, Denmark, April 12, 2002 (PRIMEZONE) --  In June 2001 Pharmexa announced that it had in-licensed a vector-cell production system from GlaxoSmithKline (NYSE:GSK) for use in Pharmexa's AutoVac(TM) HER-2 Protein project against cancer. No further details were announced at that time.